Steroid contraception – the influence on bone metabolism
Authors:
Fait Tomáš 1,2
Authors‘ workplace:
Gynekologicko-porodnická klinika 2. LF UK a FN Motol, Praha
1; Katedra zdravotnických studií Vysoká škola polytechnická Jihlava
2
Published in:
Clinical Osteology 2024; 29(4): 122-127
Category:
Overview
The combined hormonal contraception have positive influence on bone mineral density due to its estrogen component. This effect could have clinical application in group of women with menstrual cycle´s disorders and in perimenopausal women. Extremely low doses of ethinylestradiol could forestall the achievement of bone mineral density peak. Depot medroxyprogesterone acetate is not suitable contraception for women with risk of osteoporosis.
Keywords:
bone fractures – bone mineral density – combined hormonal contraception – only gestagen contraception
Sources
Broulík P. Osteoporóza. Maxdorf: Praha 1999. ISBN 80–85800–93–4.
Fait T, Vrablik M. Hormone replacement therapy (HRT) shortages for treating menopause: What can clinicians do to relieve symptoms and concerns? Sci 2024; 6(3): 46. Dostupné z DOI: <http://dx.doi.org/10.3390/sci6030046>.
Fait T, Kushniruk N. Předčasné ovariální selhání v každodenní praxi. Gynek Porod 2022; 6 (1): 22–24.
Watts NB, Binkley N, Owens CD et al. Bone mineral denzity changes associated with pregnancy, lactation, and medical treatments in premenopausal women and effects later in life. J Womens Health (Larchmt) 2021; 30(10): 1416–1430. Dostupné z DOI: <http://dx.doi.org/10.1089/jwh.2020.8989>.
Curtis KM, Martins SL. Progestogen-only contraception and bone mineral denzity: a systematic review. Contraception 2006; 73(5): 470–487. Dostupné z DOI: <http://dx.doi.org/10.1016/j.contraception.2005.12.010>.
Fait T. Antikoncepce. 4th ed. Maxdorf: Praha 2023. ISBN 978–80–7345–773–0.
Bonjour J, Theintz G, Buchs B et al. Critical years and stages of puberty for spinal and femoral bone mass accumulation during adolescence. J Clin Endocrinol Metab 1991; 73(3): 555–563. Dostupné z DOI: <http://dx.doi.org/10.1210/jcem-73–3–555>.
Jilka RL. Cytokines, bone remodeling, and estrogen deficiency: a 1998 update. Bone 1998; 2(23): 75–81. Dostupné z DOI: <http://dx.doi.org/10.1016/s8756–3282(98)00077–5>.
Karlsson R, Eden S, von Schoultz B. Oral contraception affects osteocalcin serum profiles in young women. Osteoporosis Int 1992; 2(3): 118–121. Dostupné z DOI: <http://dx.doi.org/10.1007/BF01623817>.
Burr DB, Yoshikawa T, Tedgarten D et al. Exercise and OC use supress the normal age-related increase in bone mass and strength of the femoral neck in women 18–31 years of age. Bone 2000; 27(6): 855–863. Dostupné z DOI: <http://dx.doi.org/10.1016/s8756–3282(00)00403–8>.
Polatti F, Perotti F, Filippa N et al. Bone mass and long-term monophasic oral contraceptive treatment in young women. Contraception 1995; 51(4): 221–224. Dostupné z DOI: <http://dx.doi.org/10.1016/0010–7824(95)00036-a>.
Mais V, Fruzetti F, Ajossa S et al. Bone metabolism in young women taking a monophasic pill containing 20 mg ethinylestradiol: prospective study. Contraception 1993; 48(5): 445–452. Dostupné z DOI: <http://dx.doi.org/10.1016/0010–7824(93)90134-s>.
Rodin A, Chapman M, Foelman I. Bone density in users of combined oral contraception. Br J Fam Plann 1991; 16: 125–129.
Recker RR, Davies KM, Hinders SM et al. Bone gain in young adult women. JAMA 1992; 268(17): 2403–2408.
Paoletti AM, Orru M, Floris S et al. Evidence that treatment with monophasic oral contraceptive formulations containing ethinylestradiol plus gestodene reduces bone resorption in young women. Contraception 2000; 61(4): 259–263. Dostupné z DOI: <http://dx.doi.org/10.1016/s0010–7824(00)00104–9>.
Čepický P. Kombinovaná hormonální kontracepce s extrémně nízkou dávkou estrogenu. Mod Gyn Por 2000; 9(4): 719–721.
Teslík L. Komentář. Praktické rady pro předepisování hormonální antikoncepce mladistvým. Gyn po Promoci 2002; 4: 33–34.
Makalová D, Hořejší J. Antikoncepce pro mladistvé. Mod Gyn Por 2001; 10(3): 456–462.
Seeman E, Szmukler GI, Formica C et al. Osteoporosis in anorexia nervosa: the influence of peak bone density, bone loss, oral contraceptive use and exercise. J Bone Miner Res 1992; 7(12): 1467–1474. Dostupné z DOI: <http://dx.doi.org/10.1002/jbmr.5650071215>.
Haenggi W, Casez JP, Birkhaeuser MH et al. Bone mineral density in young women with long-standing amenorrhea: limited effect of hormone replacement therapy with ethinyl estradiol and desogestrel. Osteoporosis Int 1994; 4(2): 99–103. Dostupné z DOI: <http://dx.doi.org/10.1007/BF01623232>.
Shargil AA. Hormone replacement therapy in perimenopausal women with a triphasic contraceptive compound: a three year prospective study. Int J Fertil 1985; 30(1): 18–28.
Gambacciani M, Spinetti A, Capagli B et al. Hormone replacement therapy in perimenopausal women with a low dose oral contraceptive preparation: effects on bone mineral density and metabolism. Maturitas 1994; 19: 125–131. Dostupné z DOI: <http://dx.doi.org/10.1016/0378–5122(94)90062–0>.
Gambacciani M, Spinetti A, Taponeco F et al. Longitudinal evaluation of perimenopausal vertebral bone loss: effects of low-dose oral contraceptive preparation on bone mineral density and metabolism. Obstet Gynecol 1994; 83(3): 392–396.
24.Tuppurainen M, Kröger H, Saarikoski S et al. The effect of previous oral contraceptive use on bone mineral density in perimenopausal women. Osteoporosis Int 1994; 4(2): 93–98. Dostupné z DOI: <http://dx.doi.org/10.1007/BF01623231>.
Garnero P, Sornay-Rendu E, Delmas PD. Decreased bone turnover in oral contraceptive users. Bone 1995; 16(5): 499–503. Dostupné z DOI: <http://dx.doi.org/10.1016/8756–3282(95)00075-o>.
Hreshchyshyn MM, Hopkins A, Zylstra S et al. Associations of parity, breast-feeding and birth control of pills with lumbar spine and femoral neck bone densities. Am J Obstet Gynecol 1988; 159(2): 318–322. Dostupné z DOI: <http://dx.doi.org/10.1016/s0002–9378(88)80075–9>.
Murphy S, Khaw KT, Compston JE. Lack of relationship between hip and spine bone mineral density and oral contraceptive use. Eur J Clin Invest 1993: 23(2): 108–111. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1365–2362.1993.tb00749.x>.
Horsman A, Jones M., Francis R et al. The effect of estrogen dose on postmenopausal bone loss. Engl J Med 1983; 309(23): 1405–1407. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJM198312083092301>.
Lindsay R, Tohme J, Kanders B. The effect of oral contraceptive use on vertebral bone mass in climacteric women. Contraception 1986; 34(4): 333–340. Dostupné z DOI: <http://dx.doi.org/10.1016/0010–7824(86)90086–7>.
Enzelsberger H, Metka M, Heytmanek G et al. Influence of oral contraceptive use on bone density in climacteric women. Maturitas 1988; 9(4): 375–378. Dostupné z DOI: <http://dx.doi.org/10.1016/0378–5122(88)90103-x>.
Kleerekoper M, Brienza RS, Schulz LR. Oral contraceptive use may protect against low bone mass. Arch Intern Med 1991; 151(10): 1971–1976.
Kritz-Silverstein D, Barret-Connor E. Bone mineral density in postmenopausal women as determined by prior oral contraceptive use. Am J Public Health 1993; 83(1): 100–102. Dostupné z DOI: <http://dx.doi.org/10.2105/ajph.83.1.100>.
Cooper C, Hannaford P, Croft P et al. Oral contraceptive pill use and fractures in women: a prospective study. Bone 1993; 14(1): 41–45. Dostupné z DOI: <http://dx.doi.org/10.1016/8756–3282(93)90254–8>.
Michaelson K, Baron JA, Farahmand BY et al. Oral-contraceptive use and risk of hip fracture: a case-control study. Lancet 1999; 353(9163): 1481–1484. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(98)09044–8>.
Taitel HF, Lippman JS. Effect of oral contraceptives on bone mass. Female Patient 1995, 20: 1–16.
DeCherney A. Bone-sparing properties of oral contraceptives. Am J Obstet Gynecol 1996; 174(1 Pt 1): 15–20. Dostupné z DOI: <http://dx.doi.org/10.1016/s0002–9378(96)70366–6>.
Kuohung W, Borgatta L, Stubblefield P. Low-dose oral contraceptives and bone mineral density: an evidence based analysis. Contraception 2000; 61(2): 77–82. Dostupné z DOI: <http://dx.doi.org/10.1016/s0010–7824(00)00086-x>.
Lopez LM, Grimes DA, Schulz F et al. Steroidal Contraceptives: effect on bone fractures in women. Cochrane Database Syst rev 2011; (7): CD006033. Dostupné z DOI: <http://dx.doi.org/10.1002/14651858.CD006033.pub4>.
Modesto W, Bahamondes MV, Bahamondes L. Prevalence of Low Bone Mass and Osteoporosis in Long-Term Users of the Injectable Contraceptive Depot Medroxyprogesterone Acetate. J Women’s Health (Larchmt) 2015; 24(8): 636–640. Dostupné z DOI: <http://dx.doi.org/10.1089/jwh.2014.5077>.
Clark MK, Sowers MR, Nichols S et al. Bone mineral density changes over two years in first-time users of depot medroxyprogesterone acetate. Fertil Steril 2004; 82(6): 1580–1586. Dostupné z DOI: <http://dx.doi.org/10.1016/j.fertnstert.2004.04.064>.
Golden NH. Bones and birth control in adolescent girls. J Pediatr Adolescent Gynecol 2020; 33(3): 249–254. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jpag.2020.01.003>.
Coombs CV, O´Leary TJ, Tang JC et al. Hormonal contraceptive use, bone denzity and biochemical markers of bone metabolism in British Army recruits. BMJ Mil Health 2023; 169(1): 9–16. Dostupné z DOI: <http://dx.doi.org/10.1136/bmjmilitary-2020–001745>.
Labels
Clinical biochemistry Paediatric gynaecology Paediatric radiology Paediatric rheumatology Endocrinology Gynaecology and obstetrics Internal medicine Orthopaedics General practitioner for adults Radiodiagnostics Rehabilitation Rheumatology Traumatology OsteologyArticle was published in
Clinical Osteology
2024 Issue 4
Most read in this issue
- Charcot's osteoarthropathy or Sudeck's Syndrome? A case report
- Steroid contraception – the influence on bone metabolism
- Osteoporosis and liver diseases
- What's (new) in the guidelines of the osteological societies of the German-speaking countries published in 2023